Rapid Micro Biosystems, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-03-31 was $0.00.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-06-30 was $0.00.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2022-03-31 was $0.00.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $236.08M.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $0.00.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $0.00.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Rapid Micro Biosystems, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $236.08M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-08-07 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-01 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $236.08M 10-K · filed 2023-03-10 | |
| 2021-09-30 | $236.08M 10-Q · filed 2022-11-10 |